NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis $1.43 +0.01 (+0.70%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.41▼$1.4750-Day Range$1.17▼$1.5652-Week Range$1.10▼$11.26Volume174,678 shsAverage Volume1.31 million shsMarket Capitalization$78.55 millionP/E RatioN/ADividend YieldN/APrice Target$13.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Marinus Pharmaceuticals alerts: Email Address Marinus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside864.0% Upside$13.79 Price TargetShort InterestHealthy4.92% of Shares Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews Sentiment0.14Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.27 out of 5 starsMedical Sector156th out of 936 stocksPharmaceutical Preparations Industry63rd out of 436 stocks 3.3 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Marinus Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.92% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently decreased by 42.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 60.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.55. Previous Next 1.7 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Marinus Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Marinus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.87) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Marinus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More MRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Stock News HeadlinesJuly 26 at 12:10 PM | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 26 at 11:28 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 26 at 5:45 AM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 5, 2024 in Marinus Pharmaceuticals, Inc. Lawsuit - MRNSJuly 25 at 9:55 PM | markets.businessinsider.comMarinus Pharmaceuticals (MRNS) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud LawsuitJuly 25 at 6:05 PM | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNSJuly 25 at 12:33 PM | globenewswire.comClass Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & KorsinskyJuly 25 at 9:55 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 25 at 5:45 AM | prnewswire.comThe Gross Law Firm Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNSJuly 25 at 4:34 AM | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Crosses Below Two Hundred Day Moving Average of $5.34July 25 at 2:02 AM | insidermonkey.comMarinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?July 24 at 1:44 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNSJuly 24 at 12:46 PM | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusJuly 24 at 11:15 AM | prnewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law FirmJuly 23 at 4:40 PM | msn.comMarinus Pharmaceuticals Gains Approval for Seizure Drug in ChinaJuly 23 at 11:00 AM | globenewswire.comMRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 22, 2024 | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)See More Headlines Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$13.79 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+867.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-513.80% Pretax Margin-519.24% Return on Equity-518.13% Return on Assets-81.85% Debt Debt-to-Equity Ratio5.68 Current Ratio3.07 Quick Ratio2.93 Sales & Book Value Annual Sales$30.99 million Price / Sales2.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book4.60Miscellaneous Outstanding Shares54,930,000Free Float51,935,000Market Cap$78.28 million OptionableOptionable Beta1.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Scott N. Braunstein M.D. (Age 61)CEO, President & Chairman Comp: $1.01MDr. Alex Aimetti Ph.D.Chief Scientific OfficerMs. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate AffairsMs. Martha E. Manning Esq. (Age 69)J. D., Senior VP, General Counsel & Secretary Molly CameronDirector of Corporate Communications & Investor RelationsDr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance OfficerMr. Thomas J. LyonsChief Business OfficerMr. David CzekaiSenior Vice President of Chemistry, Manufacturing & ControlsDr. Mark Paternoster Ph.D.Senior Vice President of DevelopmentDr. Dayong Li Ph.D.Senior Vice President of BiometricsMore ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTAurora CannabisNASDAQ:ACBSutro BiopharmaNASDAQ:STROEnanta PharmaceuticalsNASDAQ:ENTAAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInsiders & InstitutionsValues First Advisors Inc.Bought 52,257 shares on 7/19/2024Ownership: 0.114%Assenagon Asset Management S.A.Sold 10,368 shares on 7/18/2024Ownership: 0.475%SG Americas Securities LLCBought 29,178 shares on 7/12/2024Ownership: 0.053%Ikarian Capital LLCBought 212,200 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCSold 8,200 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MRNS Stock Analysis - Frequently Asked Questions How have MRNS shares performed this year? Marinus Pharmaceuticals' stock was trading at $10.87 at the start of the year. Since then, MRNS shares have decreased by 86.8% and is now trading at $1.43. View the best growth stocks for 2024 here. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, hitting analysts' consensus estimates of ($0.68). The biopharmaceutical company had revenue of $7.68 million for the quarter, compared to analyst estimates of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative trailing twelve-month return on equity of 518.13%. When did Marinus Pharmaceuticals' stock split? Shares of Marinus Pharmaceuticals reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Marinus Pharmaceuticals' major shareholders? Marinus Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.47%), Values First Advisors Inc. (0.11%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include Scott Braunstein, Steven Pfanstiel, Christina Shafer and Martha E Manning. View institutional ownership trends. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN) and Realty Income (O). This page (NASDAQ:MRNS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.